New research at the University of Leicester to contribute to more effective drug design

publication date: Jul 22, 2011
 | 
author/source: University of Leicester
uni of LeceicesterA cutting-edge research project at the University of Leicester is aiming to improve the treatment of diabetes and cardiovascular diseases.

Figures show that cardiovascular diseases remain the number one killer in Western countries, particularly heart attacks, and most recently a warning has been issued by the World Health Organization (WHO) that Type 2 diabetes, the most common form of diabetes, will increase by as much as 80% in some regions throughout the world in the near future.

A PhD student with the Department of Cardiovascular Sciences, Hussein Rubaiy, has uncovered new information from his study, which has the potential to contribute to the design of novel and more effective drugs for the treatment of diabetes and cardiovascular diseases, e.g. high blood pressure and heart attack.

In his study, Rubaiy analysed the mechanisms of a cardiac potassium channel and its component parts, which play an important role in such vital processes as heart rhythm and tissue protection. His work has thrown more light on how the channel works and how information from drug interaction is converted into modified function.

Rubaiy commented: "This research provides important foundations of understanding on which to build future research and development of more targeted drug design. I am very optimistic that my detailed findings will find application in the pharmaceutical industry in the design or improvement of drugs for the treatment of Type 2 diabetes and cardiovascular diseases."

Dr Bob Norman, Senior Lecturer at the Department of Cardiovascular Sciences, added: "Modulation of the properties of the channel has wider potential as a target for therapies to protect tissues from damage resulting from low blood flow, as in heart attack or cardiac surgery, and possibly as a treatment for high blood pressure. Hussein Rubaiy's findings add significantly to our understanding of how these channels work and hopefully should contribute in the future to the more rational design of drugs to modify the properties of this important drug target."

For further information information visit  http://www2.le.ac.uk/offices/ssds/sd/pgrd/fpgr.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.